ACTI Active Biotech AB

Active Biotech's election committee appointed

Active Biotech's election committee appointed

PRESS RELEASE

In accordance with a decision made by the Annual General Meeting held on May 23, 2019, the Election Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2019, and the Chairman of the Board.

For the 2020 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders by votes and, accordingly, are members of the Election Committee:

Mats Arnhög, MGA Holding

Angela Langemar Olsson, Nordstjernan

Per Colleen, 4:e AP Fonden

Under the leadership of the Chairman of the Board, Michael Shalmi, the Election Committee shall prepare proposals to be presented to and decided upon at the Annual General Meeting on May 19, 2020.

Lund, November 19, 2019

Active Biotech AB (publ)

Helén Tuvesson

President and CEO

For further information, please contact:

Hans Kolam, CFO

Tel: +46 (0)46 19 20 44

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Please visit for more information.





Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund, Sweden

Tel: +46 (0)46 19 20 00



This information was submitted for publication, through the agency of the contact person set out above, at 16.00 p.m. CET on November 19, 2019.

Attachment

EN
19/11/2019

Underlying

ACTIActive Biotech AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Active Biotech AB

 PRESS RELEASE
Free
ACTI Active Biotech ...

Successful completion of the first stage of the phase IIa clinical tri...

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In th...

June 1, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

Det första steget av den kliniska fas IIa studien med naptumomab i kom...

Det första steget av den kliniska fas IIa studien med naptumomab i kombination med docetaxel har framgångsrikt slutförts och rekryteringen till andra steget av studien pågår Lund, 1 juni 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och dess partner NeoTX tillkännager idag det framgångsrika slutförandet av det första steget av en adaptiv (Simon 2 stage) klinisk fas IIa studie med naptumomab estafenatox (NAP, naptumomab), i kombination med docetaxel i patienter med avancerad icke-småcellig lungcancer (NSCLC) som tidigare har behandlats med kemoterapi och checkpointhämmare  (CPI). I studien ...

June 1, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

Annual General Meeting of Active Biotech AB

Annual General Meeting of Active Biotech AB The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2021, and that the Company’s accumulated loss shall be carried forward. The members of the Board and the CEO were discharged from liability with respect to their manag...

May 19, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

Årsstämma i Active Biotech AB

Årsstämma i Active Biotech AB Active Biotechs årsstämma hölls den 19 maj 2022. Mot bakgrund av coronaviruset genomfördes årsstämman med poströstning, utan fysiskt deltagande. Följande huvudsakliga beslut fattades. I enlighet med styrelsens förslag beslutades att ingen utdelning skulle lämnas för räkenskapsåret 2021 och att bolagets ansamlade förlust skulle balanseras i ny räkning. Styrelsens ledamöter och verkställande direktören beviljades ansvarsfrihet för 2021 års förvaltning. I enlighet med valberedningens förslag omvaldes styrelseledamöterna Michael Shalmi, Uli Hack...

May 19, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis   Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of  tasquinimod in thi...

May 18, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch